pentoxifylline has been researched along with Diabetic Glomerulosclerosis in 54 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " We have conducted a double blinded clinical trial to assess the additive effect of pentoxifylline on reduction of proteinuria among patients with type 2 DM under blockade of angiotensin system." | 9.16 | The effect of pentoxifylline on reduction of proteinuria among patients with type 2 diabetes under blockade of angiotensin system: a double blind and randomized clinical trial. ( Beladi-Mousavi, SS; Ghorbani, A; Lak, E; Omidvar, B; Vaziri, S, 2012) |
| "To compare the relative efficacy of pentoxifylline (PTX) and angiotensin-converting enzyme (ACE) inhibitor, captopril in the treatment of proteinuria of type 2 diabetic patients." | 9.11 | Comparison of the effect of pentoxifylline and captopril on proteinuria in patients with type 2 diabetes mellitus. ( Amini, M; Aminian, T; Aminorroaya, A; Gharavi, M; Janghorbani, M; Rezvanian, H, 2005) |
| "We searched bibliographic databases for trials involving pentoxifylline that reported proteinuria, glomerular filtration rate, or blood pressure." | 8.84 | The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis. ( Akbari, A; Doucette, S; Fergusson, D; Knoll, G; McCormick, BB; Sydor, A, 2008) |
| "In 1985, investigators reported that four months of pentoxifylline therapy resulted in a significant decrease in proteinuria (46 percent reduction) and plasma fibrinogen concentrations (18 percent reduction) in patients with diabetes." | 7.68 | Effects of pentoxifylline on proteinuria in normotensive patients with diabetes mellitus. ( Karam, JH; Koda-Kimble, MA; White, JR, 1990) |
| "Pentoxifylline is a drug with hemorheological actions used in the management of microcirculatory abnormalities, such as those usually seen in diabetic patients." | 6.68 | Pentoxifylline reduces proteinuria in insulin-dependent and non insulin-dependent diabetic patients. ( Amato, D; García-Bulnes, G; Guerrero-Romero, F; Paniagua-Sierra, JR; Rodríguez-Morán, M; Salas-Ramírez, M, 1995) |
| " Conclusion of this review is that short-term use of PTF may produce a significant reduction of proteinuria in subjects with diabetic and also non-diabetic kidney diseases but the reports of long-term use of PTF also show that urinary protein excretion exhibits a progressive and sustained reduction in patients treated with PTF." | 6.47 | A review of the potential benefits of pentoxifylline in diabetic and non-diabetic proteinuria. ( Abdollahi, M; Badri, S; Dashti-Khavidaki, S; Lessan-Pezeshki, M, 2011) |
| "Among the microvascular complications, diabetic nephropathy is the most frequent cause of end-stage renal disease." | 6.44 | Efficacy of pentoxifylline in the management of microalbuminuria in patients with diabetes. ( Guerrero-Romero, F; Rodríguez-Morán, M, 2008) |
| " We have conducted a double blinded clinical trial to assess the additive effect of pentoxifylline on reduction of proteinuria among patients with type 2 DM under blockade of angiotensin system." | 5.16 | The effect of pentoxifylline on reduction of proteinuria among patients with type 2 diabetes under blockade of angiotensin system: a double blind and randomized clinical trial. ( Beladi-Mousavi, SS; Ghorbani, A; Lak, E; Omidvar, B; Vaziri, S, 2012) |
| "To compare the relative efficacy of pentoxifylline (PTX) and angiotensin-converting enzyme (ACE) inhibitor, captopril in the treatment of proteinuria of type 2 diabetic patients." | 5.11 | Comparison of the effect of pentoxifylline and captopril on proteinuria in patients with type 2 diabetes mellitus. ( Amini, M; Aminian, T; Aminorroaya, A; Gharavi, M; Janghorbani, M; Rezvanian, H, 2005) |
| "From the available evidence, pentoxifylline seems to offer some beneficial effects in renal function improvement and reduction in albuminuria and proteinuria, with no obvious serious adverse effects for patients with DKD." | 4.88 | Pentoxifylline for diabetic kidney disease. ( Li, J; Liu, GJ; Shan, D; Wu, HM; Yuan, QY; Zhou, RL, 2012) |
| "We searched bibliographic databases for trials involving pentoxifylline that reported proteinuria, glomerular filtration rate, or blood pressure." | 4.84 | The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis. ( Akbari, A; Doucette, S; Fergusson, D; Knoll, G; McCormick, BB; Sydor, A, 2008) |
| "In 1985, investigators reported that four months of pentoxifylline therapy resulted in a significant decrease in proteinuria (46 percent reduction) and plasma fibrinogen concentrations (18 percent reduction) in patients with diabetes." | 3.68 | Effects of pentoxifylline on proteinuria in normotensive patients with diabetes mellitus. ( Karam, JH; Koda-Kimble, MA; White, JR, 1990) |
| "In 45 patients with type 2 diabetes mellitus (DM), we prospectively analyzed urinary excretion of N-acetyl-beta-glucosaminidase (NAG), a marker of tubular renal damage; the potential relationship with urinary protein excretion; and effects of pentoxifylline (PTF) administration." | 2.71 | Effects of pentoxifylline administration on urinary N-acetyl-beta-glucosaminidase excretion in type 2 diabetic patients: a short-term, prospective, randomized study. ( Garca, J; Maca, M; Mora, C; Muros, M; Navarro, JF, 2003) |
| "Pentoxifylline is a drug with hemorheological actions used in the management of microcirculatory abnormalities, such as those usually seen in diabetic patients." | 2.68 | Pentoxifylline reduces proteinuria in insulin-dependent and non insulin-dependent diabetic patients. ( Amato, D; García-Bulnes, G; Guerrero-Romero, F; Paniagua-Sierra, JR; Rodríguez-Morán, M; Salas-Ramírez, M, 1995) |
| "Diabetic nephropathy, or diabetic kidney disease (DKD), is the most serious complication of diabetes mellitus (DM)." | 2.53 | Pentoxifylline for Diabetic Nephropathy: an Important Opportunity to Re-purpose an Old Drug? ( Bhanot, S; Leehey, DJ, 2016) |
| "Pentoxifylline (PTF) has anti-inflammatory properties, which may be beneficial for diabetic nephropathy (DN)." | 2.52 | Efficacy and safety of combining pentoxifylline with angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in diabetic nephropathy: a meta-analysis. ( Shen, Y; Sun, ZL; Tian, ML; Zha, Y, 2015) |
| "Diabetic nephropathy is a leading cause of end-stage renal disease worldwide." | 2.50 | [Diabetic nephropathy: emerging treatments]. ( Cazenave, M; Gauthier, M; Gueutin, V; Izzedine, H, 2014) |
| " Conclusion of this review is that short-term use of PTF may produce a significant reduction of proteinuria in subjects with diabetic and also non-diabetic kidney diseases but the reports of long-term use of PTF also show that urinary protein excretion exhibits a progressive and sustained reduction in patients treated with PTF." | 2.47 | A review of the potential benefits of pentoxifylline in diabetic and non-diabetic proteinuria. ( Abdollahi, M; Badri, S; Dashti-Khavidaki, S; Lessan-Pezeshki, M, 2011) |
| "Diabetic nephropathy is the leading cause of end-stage renal disease, and both the incidence and prevalence of diabetic nephropathy continue to increase." | 2.46 | Potential new therapeutic agents for diabetic kidney disease. ( Bolton, WK; Turgut, F, 2010) |
| "In the setting of diabetic nephropathy, there is now evidence of the relevant contribution of pro-inflammatory cytokines, with special participation of tumor necrosis factor-alpha (TNF-alpha)." | 2.45 | Tumor necrosis factor-alpha as a therapeutic target for diabetic nephropathy. ( García, J; Jarque, A; Mora, C; Muros, M; Navarro-González, JF, 2009) |
| "Among the microvascular complications, diabetic nephropathy is the most frequent cause of end-stage renal disease." | 2.44 | Efficacy of pentoxifylline in the management of microalbuminuria in patients with diabetes. ( Guerrero-Romero, F; Rodríguez-Morán, M, 2008) |
| " Adult male Wistar albino rats were randomly divided into three groups: normal control (the N group), diabetic nephropathy (the DN group), and diabetic nephropathy treated with pentoxifylline at the dosage of 20 mg x kg(-1) x d(-1), intraperitoneally (the group DNP)." | 1.32 | The effects of pentoxifylline on diabetic renal changes in streptozotocin-induced diabetes mellitus. ( Canoz, O; Dusunsel, R; Gunduz, Z; Per, H; Poyrazoglu, MH; Saraymen, R; Tez, C, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (3.70) | 18.7374 |
| 1990's | 11 (20.37) | 18.2507 |
| 2000's | 14 (25.93) | 29.6817 |
| 2010's | 25 (46.30) | 24.3611 |
| 2020's | 2 (3.70) | 2.80 |
| Authors | Studies |
|---|---|
| Leehey, DJ | 3 |
| Carlson, K | 1 |
| Reda, DJ | 1 |
| Craig, I | 1 |
| Clise, C | 1 |
| Conner, TA | 1 |
| Agarwal, R | 1 |
| Kaufman, JS | 1 |
| Anderson, RJ | 1 |
| Lammie, D | 1 |
| Huminik, J | 1 |
| Polzin, L | 1 |
| McBurney, C | 1 |
| Huang, GD | 1 |
| Emanuele, NV | 1 |
| Mehanna, OM | 1 |
| El Askary, A | 1 |
| Al-Shehri, S | 1 |
| El-Esawy, B | 1 |
| Lin, YC | 1 |
| Chang, YH | 1 |
| Yang, SY | 1 |
| Wu, KD | 1 |
| Chu, TS | 1 |
| Rabizadeh, S | 1 |
| Dehghani Firouzabadi, F | 1 |
| Noshad, S | 1 |
| Esteghamati, S | 1 |
| Afarideh, M | 1 |
| Ghajar, A | 1 |
| Ganji, M | 1 |
| Saadat, M | 1 |
| Heidari, B | 1 |
| Najafi, MT | 1 |
| Nakhjavani, M | 1 |
| Esteghamati, A | 1 |
| Navarro-González, JF | 3 |
| Sánchez-Niño, MD | 1 |
| Donate-Correa, J | 1 |
| Martín-Núñez, E | 1 |
| Ferri, C | 1 |
| Pérez-Delgado, N | 1 |
| Górriz, JL | 1 |
| Martínez-Castelao, A | 1 |
| Ortiz, A | 1 |
| Mora-Fernández, C | 2 |
| Kapoor, S | 1 |
| Sun, HK | 2 |
| Han, SY | 3 |
| Tang, X | 1 |
| Bridson, G | 1 |
| Ke, J | 1 |
| Wu, L | 1 |
| Erol, H | 1 |
| Graham, P | 1 |
| Lin, CH | 1 |
| Braman, V | 1 |
| Zhao, H | 1 |
| Liu, JF | 1 |
| Lin, ZJ | 1 |
| Cheng, C | 1 |
| Gueutin, V | 1 |
| Gauthier, M | 1 |
| Cazenave, M | 1 |
| Izzedine, H | 1 |
| Muros de Fuentes, M | 1 |
| Chahin, J | 3 |
| Méndez, ML | 3 |
| Gallego, E | 3 |
| Macía, M | 3 |
| del Castillo, N | 1 |
| Rivero, A | 3 |
| Getino, MA | 1 |
| García, P | 1 |
| Jarque, A | 2 |
| García, J | 7 |
| Kao, CC | 1 |
| Wu, MS | 1 |
| He, T | 1 |
| Cooper, ME | 1 |
| Tian, ML | 1 |
| Shen, Y | 1 |
| Sun, ZL | 1 |
| Zha, Y | 1 |
| An, ZM | 1 |
| Dong, XG | 1 |
| Guo, Y | 1 |
| Zhou, JL | 1 |
| Qin, T | 1 |
| Bhanot, S | 1 |
| Lai, TS | 1 |
| Chiang, WC | 2 |
| Chen, YM | 2 |
| Sönmez, MF | 1 |
| Dündar, M | 1 |
| Pena-Polanco, JE | 1 |
| Fried, LF | 1 |
| Diskin, CJ | 1 |
| Muros, M | 3 |
| Mora, C | 8 |
| Leyva-Jiménez, R | 1 |
| Rodríguez-Orozco, AR | 1 |
| Ortega-Pierres, LE | 1 |
| Ramírez-Enríquez, J | 1 |
| Gómez-García, A | 1 |
| Alvarez-Aguilar, C | 1 |
| Han, KH | 2 |
| Kim, HS | 2 |
| Kang, YS | 1 |
| Cha, DR | 1 |
| Turgut, F | 1 |
| Bolton, WK | 1 |
| Roozbeh, J | 1 |
| Banihashemi, MA | 1 |
| Ghezlou, M | 1 |
| Afshariani, R | 1 |
| Salari, S | 1 |
| Moini, M | 1 |
| Sagheb, MM | 1 |
| Badri, S | 1 |
| Dashti-Khavidaki, S | 1 |
| Lessan-Pezeshki, M | 1 |
| Abdollahi, M | 1 |
| Shan, D | 1 |
| Wu, HM | 1 |
| Yuan, QY | 1 |
| Li, J | 1 |
| Zhou, RL | 1 |
| Liu, GJ | 1 |
| Kang, SW | 1 |
| Lee, YM | 1 |
| Ahn, SH | 1 |
| Ghorbani, A | 1 |
| Omidvar, B | 1 |
| Beladi-Mousavi, SS | 1 |
| Lak, E | 1 |
| Vaziri, S | 1 |
| Navarro, JF | 7 |
| Maca, M | 1 |
| Garca, J | 1 |
| Gunduz, Z | 1 |
| Canoz, O | 1 |
| Per, H | 1 |
| Dusunsel, R | 1 |
| Poyrazoglu, MH | 1 |
| Tez, C | 1 |
| Saraymen, R | 1 |
| Aminorroaya, A | 1 |
| Janghorbani, M | 1 |
| Rezvanian, H | 1 |
| Aminian, T | 1 |
| Gharavi, M | 1 |
| Amini, M | 1 |
| Dávila-Esqueda, ME | 1 |
| Vertiz-Hernández, AA | 1 |
| Martínez-Morales, F | 1 |
| Lin, SL | 1 |
| Lai, CF | 1 |
| Tsai, TJ | 1 |
| Hsieh, BS | 1 |
| Rodriguez-Morán, M | 3 |
| González-González, G | 1 |
| Bermúdez-Barba, MV | 1 |
| Medina de la Garza, CE | 1 |
| Tamez-Pérez, HE | 1 |
| Martínez-Martínez, FJ | 1 |
| Guerrero-Romero, F | 3 |
| Milena, FJ | 1 |
| León, C | 1 |
| McCormick, BB | 1 |
| Sydor, A | 1 |
| Akbari, A | 1 |
| Fergusson, D | 1 |
| Doucette, S | 1 |
| Knoll, G | 1 |
| Spesivtseva, VG | 1 |
| Kasabian, IN | 1 |
| Mamaeva, GG | 1 |
| Kukes, VG | 1 |
| Paniagua-Sierra, JR | 1 |
| García-Bulnes, G | 1 |
| Salas-Ramírez, M | 1 |
| Amato, D | 1 |
| Ely, H | 1 |
| Tripathi, K | 1 |
| Prakash, J | 1 |
| Appaiha, D | 1 |
| Srivastava, PK | 1 |
| McDaniel, MD | 1 |
| James, SH | 1 |
| Meyers, AM | 1 |
| Wardle, EN | 1 |
| Gorson, DM | 1 |
| White, JR | 1 |
| Karam, JH | 1 |
| Koda-Kimble, MA | 1 |
| Ferrari, E | 1 |
| Fioravanti, M | 1 |
| Patti, AL | 1 |
| Viola, C | 1 |
| Solerte, SB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| CSP #2008 - Pentoxifylline in Diabetic Kidney Disease[NCT03625648] | Phase 4 | 2,510 participants (Anticipated) | Interventional | 2019-11-18 | Recruiting | ||
| Effects of Calcitriol on Podocytes in Diabetic Kidney Disease Patients: Assessment of Urine Podocin, Urine Nephrin, Urine Interleukin-6, Urine KIM-1, Plasma Renin, and Albuminuria[NCT05298163] | 120 participants (Anticipated) | Interventional | 2022-04-30 | Not yet recruiting | |||
| Interaction of Polymorphism rs35652124 With Curcumin Supplementation on NFE2L2 Gene Expression, Antioxidant Capacity and Renal Function in Patients With Early Diabetic Nephropathy[NCT03262363] | Phase 2/Phase 3 | 176 participants (Anticipated) | Interventional | 2018-08-01 | Not yet recruiting | ||
| Phase 3 Study of the Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Renal Outcomes in Humans With Diabetic Kidney Disease[NCT01847313] | Phase 3 | 20 participants (Actual) | Interventional | 2013-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Spot urine sample for MCP-1 and creatinine (NCT01847313)
Timeframe: Up to 26 weeks
| Intervention | ng/mmol (Mean) |
|---|---|
| Liraglutide | 27.9 |
| Control | 24.3 |
Serum sample for sCD163 (NCT01847313)
Timeframe: Up to 26 weeks
| Intervention | ng/ml (Mean) |
|---|---|
| Liraglutide | 82 |
| Control | 84 |
Spot urine sample for MCP-1 and creatinine (NCT01847313)
Timeframe: Up to 26 weeks
| Intervention | pg/mmol (Mean) |
|---|---|
| Liraglutide | 27.9 |
| Control | 24.3 |
Albuminuria as Measured by 24 Hour Albumin Excretion Rate (NCT01847313)
Timeframe: Up to 26 weeks
| Intervention | µg/min (Mean) |
|---|---|
| Liraglutide | 144.1 |
| Control | 132.4 |
14 reviews available for pentoxifylline and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Targeting Inflammation in Diabetic Kidney Disease: Is There a Role for Pentoxifylline?
Topics: Animals; Diabetes Mellitus; Diabetic Nephropathies; Humans; Inflammation; Multicenter Studies as Top | 2020 |
Update of pathophysiology and management of diabetic kidney disease.
Topics: Albuminuria; Biomarkers; Diabetic Nephropathies; Disease Progression; Humans; Kidney Failure, Chroni | 2018 |
[Diabetic nephropathy: emerging treatments].
Topics: Adrenocorticotropic Hormone; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoc | 2014 |
Efficacy and safety of combining pentoxifylline with angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in diabetic nephropathy: a meta-analysis.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Blood Press | 2015 |
Pentoxifylline for Diabetic Nephropathy: an Important Opportunity to Re-purpose an Old Drug?
Topics: Animals; Clinical Trials as Topic; Diabetic Nephropathies; Disease Progression; Humans; Kidney Failu | 2016 |
Established and Emerging Strategies in the Treatment of Chronic Kidney Disease.
Topics: Allopurinol; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bicarbonate | 2016 |
Tumor necrosis factor-alpha as a therapeutic target for diabetic nephropathy.
Topics: Animals; Cytokines; Diabetic Nephropathies; Humans; Immunity, Innate; Pentoxifylline; Tumor Necrosis | 2009 |
Potential new therapeutic agents for diabetic kidney disease.
Topics: Amides; Animals; Clinical Trials as Topic; Connective Tissue Growth Factor; Diabetic Nephropathies; | 2010 |
A review of the potential benefits of pentoxifylline in diabetic and non-diabetic proteinuria.
Topics: Animals; Chronic Disease; Diabetic Nephropathies; Disease Progression; Humans; Kidney Diseases; Kidn | 2011 |
Pentoxifylline for diabetic kidney disease.
Topics: Albuminuria; Anti-Inflammatory Agents, Non-Steroidal; Diabetic Nephropathies; Humans; Pentoxifylline | 2012 |
The renoprotective potential of pentoxifylline in chronic kidney disease.
Topics: Cell Proliferation; Diabetic Nephropathies; Humans; Kidney Failure, Chronic; Pentoxifylline; Phospho | 2005 |
Efficacy of pentoxifylline in the management of microalbuminuria in patients with diabetes.
Topics: Albuminuria; Animals; Diabetic Angiopathies; Diabetic Nephropathies; Disease Models, Animal; Glomeru | 2008 |
The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Captopril; Diabetic Nephropat | 2008 |
Can pentoxifylline prevent renal disease?
Topics: Diabetic Nephropathies; Glomerulonephritis; Humans; Nephritis, Interstitial; Pentoxifylline; Phospho | 1998 |
14 trials available for pentoxifylline and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Pentoxifylline in diabetic kidney disease (VA PTXRx): protocol for a pragmatic randomised controlled trial.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerular Filtration Rate; Humans; Multicenter S | 2021 |
Beneficial Effects of Pentoxifylline Plus Losartan Dual Therapy in Type 2 Diabetes with Nephropathy.
Topics: Atrial Natriuretic Factor; C-Reactive Protein; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dr | 2018 |
Effects of Pentoxifylline on Soluble Klotho Concentrations and Renal Tubular Cell Expression in Diabetic Kidney Disease.
Topics: Adult; Aged; Albuminuria; Animals; Cells, Cultured; Diabetes Mellitus, Type 2; Diabetic Nephropathie | 2018 |
Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial.
Topics: Aged; Albumins; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Female; Glom | 2015 |
[Effect of pentoxifylline on the evolution of diabetic nephropathy].
Topics: Diabetic Nephropathies; Double-Blind Method; Female; Humans; Male; Middle Aged; Pentoxifylline; Phos | 2009 |
Captopril and combination therapy of captopril and pentoxifylline in reducing proteinuria in diabetic nephropathy.
Topics: Adult; Aged; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Captopril; Chi-Square D | 2010 |
The effect of pentoxifylline on reduction of proteinuria among patients with type 2 diabetes under blockade of angiotensin system: a double blind and randomized clinical trial.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Humans; Male; Middle | 2012 |
Effects of pentoxifylline administration on urinary N-acetyl-beta-glucosaminidase excretion in type 2 diabetic patients: a short-term, prospective, randomized study.
Topics: Acetylglucosaminidase; Aged; Anti-Inflammatory Agents, Non-Steroidal; Diabetes Mellitus, Type 2; Dia | 2003 |
Comparison of the effect of pentoxifylline and captopril on proteinuria in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Captopril; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Femal | 2005 |
Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dr | 2005 |
Effects of pentoxifylline on the urinary protein excretion profile of type 2 diabetic patients with microproteinuria: a double-blind, placebo-controlled randomized trial.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Humans; | 2006 |
[Use of trental and complamine in the microcirculatory disorders of diabetes mellitus].
Topics: Adult; Aged; Blood; Clinical Trials as Topic; Diabetic Angiopathies; Diabetic Nephropathies; Female; | 1980 |
Pentoxifylline reduces proteinuria in insulin-dependent and non insulin-dependent diabetic patients.
Topics: Adult; Albuminuria; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Do | 1995 |
Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration.
Topics: Aged; Diabetic Nephropathies; Female; Humans; Male; Middle Aged; Pentoxifylline; Prospective Studies | 1999 |
26 other studies available for pentoxifylline and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Effect of phosphodiesterase inhibitors on renal functions and oxidant/antioxidant parameters in streptozocin-induced diabetic rats.
Topics: Animals; Antioxidants; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Hyperglycemia; Hypog | 2018 |
The renoprotective effects of pentoxifylline: beyond its role in diabetic nephropathy.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Hypoxia; Kidney Tubules; Male; Pen | 2013 |
In reply.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Hypoxia; Kidney Tubules; Male; Pen | 2013 |
Quantitative analyses of CTP-499 and five major metabolites by core-structure analysis.
Topics: Animals; Chromatography, High Pressure Liquid; Diabetic Nephropathies; Dogs; Limit of Detection; Pen | 2014 |
Renoprotective effect of pentoxifylline in advanced chronic kidney disease.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Diabetic Nephropathies; | 2015 |
Diabetic nephropathy: renoprotective effects of pentoxifylline in the PREDIAN trial.
Topics: Aged; Albuminuria; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Free Radi | 2014 |
Effects and clinical significance of pentoxifylline on the oxidative stress of rats with diabetic nephropathy.
Topics: Animals; Biomarkers; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Gene Expression Regula | 2015 |
Pentoxifylline: Evidence strong enough for renoprotection?
Topics: Diabetic Nephropathies; Humans; Kidney Failure, Chronic; Pentoxifylline; Phosphodiesterase Inhibitor | 2016 |
Ameliorative effects of pentoxifylline on NOS induced by diabetes in rat kidney.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Kidney; Male; Nitric Oxide Synthas | 2016 |
The promise of pentoxifylline and interference with the renin-angiotensin system in diabetic nephropathy.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Diabetic Nephropathies; | 2009 |
Prolonged administration enhances the renoprotective effect of pentoxifylline via anti-inflammatory activity in streptozotocin-induced diabetic nephropathy.
Topics: Animals; Anti-Inflammatory Agents; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Chemokin | 2010 |
Effect of phosphodiesterase inhibitor on diabetic nephropathy.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Hypoxia; Kidney Tubules; Male; Pen | 2012 |
Phosphodiesterase inhibitor improves renal tubulointerstitial hypoxia of the diabetic rat kidney.
Topics: Animals; Cell Line; Cobalt; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, | 2012 |
The effects of pentoxifylline on diabetic renal changes in streptozotocin-induced diabetes mellitus.
Topics: Animals; Biopsy, Needle; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, An | 2004 |
Comparative analysis of the renoprotective effects of pentoxifylline and vitamin E on streptozotocin-induced diabetes mellitus.
Topics: Animals; Antioxidants; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Hypertrophy; Kidney; | 2005 |
Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Cytokines; Diabetic Nephropathies; G | 2006 |
Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Cytokines; Diabetic Nephropathies; G | 2006 |
Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Cytokines; Diabetic Nephropathies; G | 2006 |
Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Cytokines; Diabetic Nephropathies; G | 2006 |
Is pentoxifylline the drug of the decade?
Topics: Clinical Trials as Topic; Diabetic Nephropathies; Diabetic Neuropathies; Diabetic Retinopathy; Human | 1994 |
Pentoxifylline in management of proteinuria in diabetic nephropathy.
Topics: Diabetic Nephropathies; Glomerular Filtration Rate; Humans; Pentoxifylline; Proteinuria | 1993 |
A 52-year-old woman with diabetes and claudication.
Topics: Coronary Disease; Decision Making; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Diabetic Nephro | 1998 |
Microangiopathic hemolytic anemia as a complication of diabetes mellitus.
Topics: Anemia, Hemolytic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Erythro | 1998 |
Reduction of macroalbuminuria with pentoxifylline in diabetic nephropathy. Report of three cases.
Topics: Aged; Aged, 80 and over; Albuminuria; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic | 1998 |
Effects of pentoxifylline on the haematologic status in anaemic patients with advanced renal failure.
Topics: Aged; Anemia; Diabetic Nephropathies; Erythropoietin; Female; Hematologic Agents; Humans; Kidney Fai | 1999 |
Antiproteinuric effect of pentoxifylline in patients with diabetic nephropathy.
Topics: Albuminuria; Diabetic Nephropathies; Humans; Pentoxifylline; Proteinuria; Tumor Necrosis Factor-alph | 1999 |
Nephropathy in type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Pentoxifylline; Tumor Necrosis Factor-alp | 2000 |
Effects of pentoxifylline on proteinuria in normotensive patients with diabetes mellitus.
Topics: Adult; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Fibrino | 1990 |
Effects of long-term treatment (4 years) with pentoxifylline on haemorheological changes and vascular complications in diabetic patients.
Topics: Adult; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephrop | 1987 |